nadifloxacin has been researched along with Exanthem in 2 studies
nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation." | 1.39 | Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Herzog, J; Lang, H; Möhler, M; Schimanski, CC; Theobald, M; Wehler, TC, 2013) |
| "Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients." | 1.38 | Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. ( Bölke, E; Budach, W; Buhren, BA; Eames, T; Ehmann, LM; Gerber, PA; Hetzer, S; Homey, B; Matuschek, C; Meller, S; Schrumpf, H; Wollenberg, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wehler, TC | 1 |
| Graf, C | 1 |
| Möhler, M | 1 |
| Herzog, J | 1 |
| Berger, MR | 1 |
| Gockel, I | 1 |
| Lang, H | 1 |
| Theobald, M | 1 |
| Galle, PR | 1 |
| Schimanski, CC | 1 |
| Gerber, PA | 1 |
| Meller, S | 1 |
| Eames, T | 1 |
| Buhren, BA | 1 |
| Schrumpf, H | 1 |
| Hetzer, S | 1 |
| Ehmann, LM | 1 |
| Budach, W | 1 |
| Bölke, E | 1 |
| Matuschek, C | 1 |
| Wollenberg, A | 1 |
| Homey, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors[NCT04864717] | Phase 4 | 98 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for nadifloxacin and Exanthem
| Article | Year |
|---|---|
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibo | 2013 |
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.
Topics: Administration, Topical; ErbB Receptors; Exanthema; Fluoroquinolones; Humans; Isotretinoin; Mometaso | 2012 |